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ABSTRACT
Objective: Although health-related quality of life (HRQOL)
has been included in multiple Parkinson’s disease (PD) clin-
ical trials, little is known about how HRQOL responds to
treatments over time. Here we assess the effect of therapy on
HRQOL and explore factors that inﬂuence the HRQOL pro-
ﬁles and subdomains.
Method: A total of 301 subjects with early PD were rand-
omized to either initial pramipexole or initial levodopa and
followed every 3 months over a 4-year period. To estimate
health outcomes, we used EQ-5D and PDQUALIF. We cal-
culated the incremental effectiveness as the accumulated dif-
ference in the total HRQOL over time between treatments.
The subgroup analyses (by sex, race, age, baseline patient
characteristics, and occurrence of adverse events) were con-
ducted using the same approach. Sensitivity analysis was per-
formed to test the effect of missing data imputation on the
results.
Results: All three HRQOL measures resulted in similar pro-
ﬁles over time characterized by initial improvement over the
ﬁrst 3 to 6 months and followed by a gradual decline in years
2, 3, and 4. The difference in HRQOL between the treatment
arms widened in favor of pramipexole in years 3 and 4 for all
HRQOL measures used (EQ-5D: Y3 0.048, P = 0.03; Y4
0.071, P = 0.04). Our analyses suggested that the effect of
pramipexole on HRQOL was mediated through nonmotor
functions, whereas levodopa improved primarily motor
domains of HRQOL.
Conclusion: Our results suggest that pramipexole and levo-
dopa affect patient HRQOL via improvement on different
domains of well-being: nonmotor effect for pramipexole and
mobility improvement for levodopa.
Keywords: health-related quality of life, levodopa, longitudi-
nal assessment, Parkinson’s disease, pramipexole.
Introduction
Recent clinical trials comparing initial treatment with
dopamine agonists to initial levodopa therapy in early
Parkinson’s disease (PD) have shown that each treat-
ment policy generates distinct effect proﬁles [1–3]. Ini-
tial use of dopamine agonists compared with initial use
of levodopa results in reduced risk of developing dys-
kinesias and wearing off over the ﬁrst 4 to 5 years of
treatment. Initial use of levodopa compared with
dopamine agonists, however, results in a sustained ﬁve-
to seven-point improvement on the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) [1,2] and signiﬁcantly
less somnolence and edema. Treatment guidelines have
stated that both are options as initial therapy and the
available evidence does not favor one treatment option
over another.
Several types of outcomes are used in patient out-
comes research, including cost-effectiveness studies.
The concept of health-related quality of life (HRQOL)
was developed to evaluate quantitatively person’s well-
being [4, 5]. Utility scores reﬂect person’s preferences
for health states. Utilities are used as weights when cal-
culating quality-adjusted life-years (QALYs) that cap-
ture both duration of life in a particular health state
and utility of that state [6–8]. Health states could be
deﬁned by their HRQOL. Utilities are assessed using
preference-based methods, such as time trade-off for
EQ-5D [9]. Visual analog scale is often used for sim-
plicity but it does not provide utility values. HRQOL
and utility evaluations are different from the assess-
ment of health status that is typically performed via
health status questionnaires [10].
Prior studies have shown that HRQOL is corre-
lated with important aspects of PD. Cross-sectional
studies in PD have shown that HRQOL is inﬂuenced
by age, disease severity, depression, sleep-related
events, and motor ﬂuctuations [11–14]. Longitudinal
studies [15,16] have shown that quality of life in PD
patients decreases as the disease progresses. Although
HRQOL assessments have been included in multiple
PD clinical trials, little is known about differential
effects of treatments on HRQOL of PD population
over time.
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The 4-year trial [2] comparing initial pramipexole
and initial levodopa showed that between the treat-
ment arms there was no difference in the mean changes
in the HRQOL scores from the 48-month visit to the
baseline visit. In this study, we estimate longitudinal
models to characterize HRQOL proﬁles taking into
account the HRQOL values for all visits and accumu-
late gains and losses over time, by treatment arm [17].
This approach takes into account the transient interim
values of HRQOL during the trial rather than ignoring
dynamic patterns in HRQOL between randomization
and the end of the trial. This may be of particular rel-
evance given that the beneﬁcial quality of life effects
associated with delaying dopaminergic complications
by using initial dopamine agonists instead of levodopa
may be delayed and accrue over years of therapy [2].
Using this method, we address the following ques-
tions: 1) in early PD patients, which treatment alter-
native generates more beneﬁt in terms of HRQOL, and
2) how does the difference in HRQOL gains between
treatments change as time goes on. In addition, we
explore whether patients who experience adverse
events (dyskinesias, edema, and somnolence) have
worse quality of life than patients who do not experi-
ence adverse events.
Methods
Overview of Clinical Trial
The trial was a randomized, double-blinded, placebo-
controlled study that randomly assigned 301 subjects
with early PD to either initial levodopa (n = 150) or
initial pramipexole (n = 151) with the option in both
arms of adding open-label levodopa for emerging dis-
ability [18]. Eligible subjects were persons 30 years or
older who had PD for less than 7 years, Hoehn and
Yahr scale (HY) [19] stage I–III, and who required
dopaminergic anti-PD therapy at the time of enroll-
ment [18]. Enrollment occurred between October
1996 and August 1997 at 22 academic movement dis-
order clinics in the United States (17 sites) and Canada
(ﬁve sites). The 2- and 4-year trial results are reported
elsewhere [1,2,18,20].
Health-Related Quality of Life Assessments
The HRQOL was measured using generic (EuroQol
group instrument including EQ-5D and EQ-VAS) [9,
21] and PD-speciﬁc (PDQUALIF [22]) instruments at
baseline and 10, 26, 52, 78, 102, 130, 156, 182, and
208 weeks after randomization. The HRQOL instru-
ments were self-administered during the face-to-face
study visit in a quiet clinic room, and were the ﬁrst
instruments administered during the study visits.
We chose EQ-5D as the primary HRQOL measure
because this instrument provides a measure of utility
and, hence, allow us to estimate effectiveness in QALY
units. In addition, EQ-5D has been tested for use in the
elderly with PD [23,24]. ED-VAS and PDQUALIF do
not yield utility values but were included 1) to examine
similarities and differences between HRQOL values
obtained via different tools; and 2) to reemphasize
trends. Changes in the EQ-5D over time were denoted
as QALYs gained or lost. Changes in the EQ-VAS and
PDQUALIF over time are referred to as VAS-t and
PDQUALIF-t.
EQ-5D. The EQ-5D consists of two main compo-
nents: patient health state classiﬁcation component
with a set of weights to assign a utility value (denoted
here as EQ-5D) to each health state and a visual analog
scale (EQ-VAS). The health classiﬁcation component is
deﬁned over ﬁve domains of health: mobility, self-care,
usual activity, pain, and depression/anxiety. Each of
the ﬁve domains is categorized into three severity levels
and responses are combined by a scoring algorithm to
produce a summary score between −0.594 (the worst
health state) and 1.0 (the best health state), with 0
anchored at death. Utility values for health states are
based on time–trade-off responses taken from a sample
of the UK population. The EQ-VAS is a thermometer-
type scale with 101 tick marks on which the subject
rates his or her current health state on a scale from 0 to
100, with 0 corresponding to the lowest score (worst
imaginable health) and 100 corresponding to the best
imaginable health.
The Parkinson’s disease quality of life scale
(PDQUALIF). The PDQUALIF is a disease-speciﬁc
HRQOL instrument, which consists of 33 patient self-
administered questions. The questions evaluate
changes in person’s severity of disease, independence in
performing activities of daily living (ADLs), social
interactions and emotional status as perceived by the
patient. Preliminary reliability and validity have been
demonstrated on a sample of PD patients with varying
severity of PD symptoms [22]. In the original instru-
ment, higher PDQUALIF scores represent greater dis-
ability. To make the interpretation consistent with the
EQ-5D, we reversed the scoring of the PDQUALIF by
dividing the score by 100 and subtracting that from 1
so that higher scores represent better HRQOL.
Imputation of Missing HRQOL Data
Overall, 18% of HRQOL data were missing (547 out
of 3010 observations), either in the middle of the trial
(intermittent missing, 1%) or at the end of the 4-year
period as a result of early study termination (dropout
missing, 17%). In the pramipexole group, 11 subjects
withdrew for somnolence, ﬁve for edema, and one for
both. In the levodopa group, three withdrew for dys-
kinesias, and one for somnolence. For patients who
died during the study (three deaths in the levodopa
group and two in the pramipexole group were not
treatment-related), HRQOL for all visits after death
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was assigned to zero. For each dependent measure
(EQ-5D, EQ-VAS or PDQUALIF), missing data were
imputed using a multivariate ﬁxed-effect (FE) model
similar to the approach recommended by Engels and
Diehr [25]. The dependent variable, Yit, was the dif-
ference between the baseline HRQOL score and the
score for each following visit. Independent variables
included treatment, baseline patient characteristics, a
set of variables describing baseline health status, trial-
related variables, a series of indicators for each study
visit (number of weeks after randomization), and a
ﬁxed individual component used to account for indi-
vidual patient trends in HRQOL over time. Health
status at baseline included the number of self-reported
comorbidities and a proxy for mental health problems
(depression/anxiety) based on the Anxiety/Depression
item of the EQ-5D questionnaire (answer of 0 = none,
1 = some, 2 = severe). Trial-related variables included
treatment assigned at randomization, trial completion
status, whether the subject was on open-label levo-
dopa at the time of the visit, and markers indicating
whether the subject dropped-out by the next visits and
whether the previous visit was missing. Originally we
included the independent variables describing adverse
events (presence of dyskinesias, somnolence, edema,
wearing offs or on/off effects) in the model. But
because these variables and their interactions with
treatment and time were not signiﬁcant, independently
or jointly, at P = 0.05 level, they were omitted from
the ﬁnal model.
We imputed Yit for missing data by calculating
prediction it using the above independent variables,
all of which were observed, and μit, the estimated indi-
vidual-level FE. We assumed that HRQOL data were
missing at random (MAR), conditional on observed
subject characteristics and individual FE. All the
results presented include all 301 subjects. We used
STATA Statistical Software Release 8.0 (STATA Corpo-
ration, College Station, TX, 2003) for the modeling
and SAS for Windows Version 8 (The SAS Institute,
Cary, NC, 2001) for data manipulations.
Determining the Effectiveness of Treatment Strategies
We generated normalized quality of life proﬁles for
each treatment group by plotting the mean change in
the HRQOL score from baseline to each study visit
using the EQ-5D, the EQ-VAS, and the PDQUALIF
[26,27]. We estimated the effectiveness of the
intervention as the difference in areas under the nor-
malized HRQOL proﬁle between the treatments,
ΔÊ = pramipexole − levodopa. To obtain the present
discounted values of HRQOL, all measures were dis-
counted at 3% annually. We generated bootstrapped
(1000 iterations resampled by person) standard errors
of the areas under the appropriate HRQOL proﬁles
and of the estimate of incremental effectiveness (ΔÊ).
With each redrawn sample of the bootstrap, we re-
Yˆ
estimated the imputation model and recalculated the
point estimates. Thus, the reported standard errors
incorporated uncertainty due to the imputation as well
as uncertainty due to sampling.
To identify subpopulations with differential treat-
ment effects, we examined the effect of the 4 years of
therapy on HRQOL in the following groups: males,
females [13], subjects age 65 and over, subjects under
65 years of age, subjects with the lowest baseline
HRQOL score and the highest baseline HRQOL
scores (for each of the EQ-5D, EQ-VAS, PDQUALIF)
[11, 15], and those with self-reported depression/anx-
iety as measured by the EQ-5D. Areas under each
treatment HRQOL proﬁle and the difference between
the treatment arms were estimated as described above.
Exploratory EQ-5D Analyses
Sensitivity analyses on imputation of missing data.
We conducted sensitivity analyses to assess the conse-
quence of imputation on the HRQOL estimates. In
particular, we varied assumptions about the quality of
life proﬁles immediately after dropout. We considered
four scenarios: 1) quality of life proﬁles improved for
both treatments; 2) quality of life deteriorated for both
treatments; 3) quality of life improved for those in the
pramipexole group and deteriorated for those in the
levodopa group; and 4) quality of life improved for
those in the levodopa group and deteriorated for those
in the pramipexole group. Scenarios in which a sub-
ject’s quality of life improves after dropout include
“treatment-related” dropouts when side effects of
medication result in treatment termination and, on
drug discontinuation, quality of life improves. Scenar-
ios in which a subject’s quality of life deteriorates fur-
ther after dropout reﬂect “disease progression-related”
dropouts. To quantify the improvement or deteriora-
tion in HRQOL in each of the scenarios, we estimated
regression models that identiﬁed a decline before drop-
out (a deterioration of 0.078 QALY in the pramipexole
arm and 0.065 QALY in the levodopa arm), and we
assumed that the decline either continued (further
deterioration of the same amounts after dropout) or
reversed (improvements of the same amounts after
dropout) until the 48th month’s visit.
In addition to the FE approach for imputing missing
data as described above, we also tested standard meth-
ods for the imputation of missing data: 1) imputation
of the mean (IOM); 2) last observation carried forward
(LOCF); and 3) imputation conditional on individual
baseline characteristics but without the individual FE
component (OLS) [28].
Association between EQ-5D and adverse events. To
explore the relationship between the treatments,
adverse events (dyskinesias, wearing off, somnolence,
and edema), and HRQOL, we compared the total gain
in HRQOL over 4 years in subjects who had and did
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not have speciﬁc complications at least once during the
trial. The presence of dyskinesias and wearing off was
determined by one investigator at each site and based
on direct observation or historical report. The presence
of edema or somnolence was determined by open-
ended questioning of subjects at each study visit. The
ﬁndings were considered signiﬁcant at P-values less
than 0.05.
EQ-5D  and  UPDRS  subscale  analysis. To provide
insights into the health status domains that constitute
HRQOL, we performed a subscale analysis of the EQ-
5D and the UPDRS [20]. We calculated the incremen-
tal 4-year gains for each of the ﬁve EQ-5D items:
mobility, self-care, usual activity, pain, and depression/
anxiety. We also applied the imputation model to the
UPDRS and calculated the incremental 4-year gains for
the total score as well as its three subscales: mental
(part I), ADLs (part II), and motor (part III). The sub-
scale gains are estimated using different scales and,
hence, they can not be compared directly. Neverthe-
less, the direction of the difference and statistical sig-
niﬁcance of these estimates provide useful information
about treatment effect.
Results
Subject Characteristics
Baseline characteristics of patients randomized to
either levodopa or pramipexole are presented in
Table 1. When measured via PDQUALIF and EQ-5D,
the baseline HRQOL scores were signiﬁcantly higher
for patients randomized to levodopa (P < 0.05). Close
to a third of all subjects reported some level of depres-
sion/anxiety at randomization, which was more prev-
alent in the pramipexole arm (38% vs. 22% in
levodopa arm, chi-square = 0.002). In addition, sub-
jects in pramipexole group on average had more
comorbidities (4.84 vs. 4.32 in levodopa group,
P = 0.04). Patients in the levodopa group, on average,
were diagnosed with PD for a longer period of time
before enrolling in the study (1.8 vs. 1.5 years for
pramipexole subjects, P = 0.03).
Prevalence of in-trial complications varied between
the treatment arms. Subjects randomized to pramipex-
ole reported higher occurrence of somnolence (38.4%
vs. 19.3% in levodopa group, P < 0.001) and edema
(41.1% vs. 13.3% in levodopa arm, P < 0.001),
whereas levodopa subjects experienced more dyskine-
sias (50.7% vs. 21.9% among pramipexole subjects,
P < 0.001) and wearing offs (59.3% vs. 45% in prami-
pexole arm, P = 0.01) (Table 1).
Estimating HRQOL Gain over Time
The HRQOL proﬁles over the 4 years for each of the
three measures were similar (Fig. 1). The proﬁles
showed an immediate gain in HRQOL in year 1 fol-
lowed by a decline over the next 3 years. The subjects
randomized to pramipexole experienced greater cumu-
lative gains over the 4 years, but the difference in total
gains did not reach statistical signiﬁcance. The incre-
mental effectiveness of pramipexole compared with
levodopa increased over time, with the largest beneﬁts
observed during the last 2 years of the trial. The dif-
ference in QALY gain between pramipexole and levo-
dopa groups was statistically signiﬁcant in the years 3
and 4 of the trial (year 3, 0.048 QALY, P = 0.03; year
4, 0.071 QALY, P = 0.04).
Table 2 shows the incremental HRQOL gains by
baseline characteristics. Males tended to have signiﬁ-
cant incremental gains in QALY due to pramipexole,
whereas females did not. Those subjects who self-
reported lower HRQOL anxiety and depression at
baseline tended to demonstrate greater gains in
Table 1 Characteristics of trial cohort
Category name Variable Levodopa mean/percent n = 150 Pramipexole mean/percent n = 151 P-value*
Demographic 
characteristics
Age (year) 
Sex (male)
60.9 (10.5)† 
66.0%
61.5 (10.1) 
63.6%
0.58
0.66
Health status PD duration 1.8 (1.7) 1.5 (1.4) 0.03
Depression/anxiety‡ 22.0% 38.4% 0.002
Number of comorbidities§ 4.34 (2.35) 4.84 (2.44) 0.04
UPDRS total 31.1 32.6 0.30
HRQOL PDQUALIF 0.73 (0.11) 0.71 (0.12) 0.04
EQ-5D 0.78 (0.18) 0.72 (0.21) 0.02
EQ-VAS 0.78 (0.12) 0.75 (0.16) 0.12
In-trial adverse 
events
Somnolence 
Edema
19.3%
13.3%
38.4%
41.1%
<0.001
<0.001
Dyskinesias 50.7% 21.9% <0.001
Wearing off 59.3% 45.0% 0.01
*Chi-square for comparison of frequency and t-test for comparison of means, levodopa versus pramipexole.
†Values in parentheses are SD.
‡Subjects who answered “I am not anxious or depressed” were classiﬁed into “no depression/anxiety” group. Subjects who answered “I am moderately/extremely anxious or
depressed” were classiﬁed into “depression/anxiety” group.
§Includes cardiovascular, pulmonary, allergic, gastrointestinal, metabolic/endocrine, renal, reproductive, musculoskeletal, dermatologic, and psychiatric categories.
HRQOL, health-related quality of life; PD, Parkinson’s disease; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.
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Figure 1 Total 4-year gains in health-related
quality of life (HRQOL): PDQUALIF, EQ-5D, EQ-
VAS. The mean change in HRQOL from baseline
was calculated at each visit (10, 26, 52, 78, 102,
130, 156, 182, and 208 weeks) for each treatment
arm using EQ-VAS (A), EQ-5D (B), and
PDQUALIF (C). The incremental differences (Δ) in
HRQOL between pramipexole and levodopa, by
year, were estimated as the area between the two
treatment proﬁles. The size of each graph was
scaled to reﬂect  the  differences  in  the
instrument  scale  (−0.594 to 1 for EQ-5D and 0
to 1 for EQ-VAS and adjusted PDQUALIF).
A
B
C
Levodopa 
Pramipexole 
– 0.1
– 0.08
– 0.06
– 0.04
– 0.02
0
0.02
0.04
Year 1                    Year 2                       Year 3                   Year 4 
Δ = – 0.001
P = 0.92 
Δ = – 0.001
P = 0.95 P = 0.10P = 0.12
Total
P = 0.18
EQ-VAS total
– 0.08
– 0.06
– 0.04
– 0.02
0
0.02
0.04
0.06
0.08
0.1
– 0.1
Year 1                    Year 2                       Year 3                   Year 4 
P = 0.54 P = 0.54 P = 0.04 P = 0.03 
EQ-5D total
Total  
P = 0.11 
Levodopa 
Pramipexole 
Levodopa 
Pramipexole 
– 0.04 
– 0.02
0
0.02 
0.04
– 0.08
– 0.06
– 0.1 
Year 1                    Year 2                      Year 3                   Year 4 
Δ = – 0.003
P = 0.71 
Δ = – 0.008
P = 0.48 P = 0.25 P = 0.36 
PDQUALIF total
Total  
P = 0.45 
Δ = 0.032 Δ = 0.062
Δ = 0.016 Δ = 0.048 Δ = 0.071
Δ = 0.149
Δ = 0.015 Δ = 0.036
Δ = 0.040
Δ = 0.014
Δ = 0.092
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HRQOL if in the pramipexole group compared with
the levodopa group, but the differences did not reach
statistical signiﬁcance for all instruments. No clear
pattern of incremental HRQOL gains or losses
emerged by age.
Sensitivity Analysis on Imputation of Missing EQ-5D Data
Under all four scenarios, the cumulative QALY gains
were greater in the pramipexole group compared with
the levodopa group (Table 3). Only under the scenario
where quality of life improves after withdrawal for
those in the pramipexole group and deteriorates for
those in the levodopa group did the incremental gains
in QALY reached statistical signiﬁcance (QALY gained
0.216, P = 0.01). When we assumed that EQ-5D
would improve for all subjects after dropping out,
treating with pramipexole resulted in the incremental
gain of 0.143 QALY (P = 0.09) compared with treating
with levodopa.
Using standard methods for missing data imputa-
tion also demonstrated a nonstatistically signiﬁcant
difference in QALYs gain by treatment arm over
4 years of therapy, and the estimates of health gains
were smaller (LOCF 0.084 QALY [SD 0.074], IOM
0.083 QALY [SD 0.077], OLS 0.082 QALY [SD
0.071]) (Fig. 2). We also performed another sensitivity
analysis by repeating the analysis after removing the
four patients with the lowest baseline EQ-5D scores,
which were all in the pramipexole arm. Neither point
estimates nor statistical signiﬁcance were substantively
affected by exclusion of the four subjects.
Association between EQ-5D and Adverse Events
There were no statistically signiﬁcant differences in
QALY gained or lost for subjects who experienced an
adverse event compared with those who did not
experience an adverse event (Table 4). Nevertheless,
several themes emerged. For the subjects in the levo-
dopa group, the presence of dyskinesias and wearing
off were associated with greater gains in HRQOL
compared with the subjects who did not experience
dyskinesias. For the subjects in the pramipexole group,
however, the relationship between HRQOL and dysk-
inesias was reversed. Pramipexole subjects who expe-
rienced dyskinesias had smaller gains in HRQOL
compared with the subjects who did not have dyski-
nesias. Subjects who experienced somnolence and
edema experienced smaller gains in HRQOL com-
pared with subjects who did not experience these
events but the differences were not statistically
signiﬁcant.
EQ-5D and UPDRS Subscale Analysis
In general, subjects randomized to initial levodopa
tended to show more improvements on physical func-
tion domains of motor and ADLs, whereas subjects
randomized to initial pramipexole tended to show
improvements in mental health domains. For example,
Table 2 Incremental changes in HRQOL over 4 years by baseline characteristics
Subpopulations
Gains in pramipexole group minus gains in levodopa group 
QALY (SD) VAS-t (SD) PDQUALIF-t (SD)
Male 0.168** (0.085) 0.119 (0.081) 0.072 (0.061)
Female 0.116 (0.131) 0.040 (0.085) −0.024 (0.069)
Greater or equal 65 years 0.193** (0.008) −0.005 (0.092) −0.054 (0.129)
Less than 65 years 0.129 (0.168) 0.160** (0.078) 0.033 (0.059)
Low HRQOL† 0.290** (0.087) 0.225* (0.127) 0.083 (0.104)
High HRQOL −0.010 (0.047) 0.015 (0.086) −0.056 (0.053)
Depression/anxiety‡ 0.236 (0.161) 0.193 (0.137) 0.075 (0.102)
No depression/anxiety 0.105 (0.077) 0.043 (0.068) 0.024 (0.055)
*P < 0.10, ** P < 0.05.
†EQ-5D: low quartile <0.64 (n = 81), high quartile ≥0.85 (n = 77); EQ-VAS: low quartile <0.70 (n = 61), high quartile ≥0.85 (n = 92); PDQUALIF: low quartile <0.20 (n = 80),
high quartile ≥0.36 (n = 74).
‡Subjects who answered, “I am not anxious or depressed” were classiﬁed into “no depression/anxiety” group. Subjects who answered, “I am moderately or extremely anxious
or depressed” were classiﬁed into “depression/anxiety” group.
HRQOL, health-related quality of life; QALY, quality-adjusted life-year.
Table 3 Sensitivity analysis on different assumptions of missing EQ-5D data
Scenario
QALY gained over 4-years (SD) Incremental QALY (SD) 
Levodopa n = 150 Pramipexole n = 151 Pramipexole–levodopa P-value
Base case 0.106 (0.082) 0.255 (0.077) 0.149 (0.094) 0.11
Qualify of life improves, both treatments 0.148 (0.057) 0.291 (0.062) 0.143 (0.086) 0.09
Quality of life declines, both treatments 0.075 (0.057) 0.176 (0.059) 0.101 (0.083) 0.22
Quality of life improves, pramipexole 0.075 (0.057) 0.291 (0.062) 0.216 (0.082) 0.01
Quality of life declines, levodopa 0.075 (0.057) 0.291 (0.062) 0.216 (0.082) 0.01
Quality of life improves, levodopa 0.148 (0.057) 0.176 (0.059) 0.028 (0.73) 0.73
Quality of life declines, pramipexole 0.148 (0.057) 0.176 (0.059) 0.028 (0.73) 0.73
QALY, quality-adjusted life-year.
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there is some evidence that those subjects randomized
to initial levodopa compared with initial pramipexole
had incremental gains on the mobility and self-care
items of the EQ-5D (mobility item: 0.603, P < 0.01,
self-care item: 0.164, P = 0.43). Those subjects rand-
omized to initial levodopa compared with initial
pramipexole also had incremental gains on the Motor
and ADL sections of the UPDRS (Motor component:
17.567, P < 0.01, ADL component: 2.849, P = 0.13).
There was less difference between the two groups on
the usual activities item of the EQ-5D (0.072,
P = 0.79).
On the other hand, those subjects randomized to
initial pramipexole compared with initial levodopa
had incremental gains on the anxiety/depression item
and the pain/discomfort items of the EQ-5D (anxiety/
depression item: 0.509, P = 0.13, pain/discomfort
item: 0.387, P = 0.21). These subjects also had incre-
Figure 2 Comparing the missing data impu-
tation approaches. Missing HRQOL data
were imputed using the following approaches:
i) imputation of the mean (IOM, solid line);
(ii) last observation carried forward (LOCF,
dash-dotted line); (iii) imputation conditional
on individual baseline characteristics but
without the ﬁxed-effect component (OLS,
dashed line); and (iv) imputation conditional
on individual baseline characteristics with
individual ﬁxed-effect component (FE, dotted
line).
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Table 4 Incremental changes in EQ-5D over 4-years by treatment assignment and adverse events
Levodopa Pramipexole 
ΔQALY (SD) P-valueN QALY (SD) N QALY (SD)
Dyskinesias 76 0.151 (0.077) 33 0.169 (0.112) 0.018 (0.074) 0.81
No dyskinesias 74 0.059 (0.135) 118 0.279 (0.079) 0.220 (0.135) 0.10
Difference between subgroups 0.092 (.115) −0.110 (0.129)
Wearing off 89 0.167 (0.095) 68 0.271 (0.095) 0.104 (0.036) 0.00
No wearing off 61 0.017 (0.117) 83 0.242 (0.084) 0.226 (0.161) 0.16
Difference between subgroups 0.150 (0.097) 0.029 (0.112)
Somnolence 29 −0.006 (0.151) 58 0.191 (0.095) 0.197 (0.064) 0.00
No somnolence 121 0.132 (0.092) 93 0.295 (0.079) 0.163 (0.128) 0.20
Difference between subgroups −0.138 (0.129) −0.104 (0.103)
Edema 20 0.093 (0.136) 62 0.224 (0.078) 0.131 (0.192) 0.50
No edema 130 0.108 (0.102) 89 0.277 (0.094) 0.169 (0.115) 0.14
Difference between subgroups −0.015 (0.153) −0.053 (0.109)
QALY, quality-adjusted life-year.
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mental gains on the Mental component of the UPDRS
(1.303, P = 0.07). There were no signiﬁcant differences
on any of the seven PDQUALIF subscales over time.
Discussion
This study demonstrates that patients treated with ini-
tial pramipexole compared with initial levodopa may
have different trends in HRQOL over the ﬁrst 4 years
of treatment. After an initial HRQOL increase with
both treatments during the ﬁrst year of therapy, there
was a decline in HRQOL over the next 3 years. The
HRQOL pattern was similar for three separate meas-
ures, two generic preference-based measures and a dis-
ease-speciﬁc quality of life measure. Even though none
of the 4-year changes in HRQOL reached statistical
signiﬁcance level of 95%, the consistency of the results
across the HRQOL instruments and the direction of
change that supported our hypotheses suggested that
our observations were not random.
Our results suggest that initial pramipexole may be
improving HRQOL compared with initial levodopa
through nonmotor mechanisms. The observed
HRQOL differences in favor of initial pramipexole
occurred despite a persistent ﬁve-point UPDRS beneﬁt
favoring levodopa (mediated via the Motor and ADL
components). The mobility item of the EQ-5D also
favored levodopa. Pramipexole is known to be effec-
tive for treating restless leg syndrome, depression,
schizophrenia, and possibly ﬁbromyalgia [29–32]. It is
possible that PD treatment with pramipexole may be
providing symptom relief or prevention through these
nonmotor mechanisms (e.g. interaction with dopamin-
ergic D2 and D3 receptors [33,34]), which in turn may
be improving self-reported HRQOL. Although not sta-
tistically signiﬁcant, the Mental component of the
UPDRS as well as the depression/anxiety and pain/dis-
comfort items on the EQ-5D favored pramipexole.
More research is needed to measure nonmotor symp-
toms and their possible contributions to HRQOL,
because they may be more important than the contri-
butions of the constructs in the commonly used motor
scales that do not concentrate on the mental health,
such as the UPDRS. The new UPDRS has a major
emphasis on nonmotor features and so it may be able
to assay the differences in these domains more effec-
tively than the currently used version.
Although not statistically signiﬁcant, our results
also provide insights into the relationship between side
effects and treatment. Dyskinesias are associated with
levodopa therapy but not with pramipexole therapy. In
addition, during the ﬁrst 2 years of therapy, dyskine-
sias in the levodopa arm were associated with
improved HRQOL [12]. Pramipexole subjects had an
option of taking open label levodopa if the original
treatment was not effective. Thus, dyskinesias in
pramipexole group occurred only in subjects for whom
the treatment did not work well and were thus asso-
ciated with lower HRQOL. We concluded that in lev-
odopa arm, dyskinesias were indicative of successful
treatment and higher HRQOL although in pramipex-
ole group dyskinesias signaled the failure of the origi-
nal pramipexole therapy and, consequently, lower
QALY gains over the 4 years. Our data also show that
the common pramipexole-associated side effects of
somnolence and edema were not associated with sig-
niﬁcant decrements in HRQOL. This may be similar to
the “quality of life paradox” reported in breast cancer
patients when estimated effect of therapy side effects
on HRQOL may be attenuated if patient adapts to
treatment toxicities [35–37]. Also, the HRQOL ques-
tionnaires used in the study asked subjects to describe
their health “today.” Hence, transient health states
(e.g. adverse events resolved by the time of assessment)
would not be captured unless they produce a lingering
effect on HRQOL (e.g. depression).
The deterioration of HRQOL after the ﬁrst year of
treatment was greater in patients treated with levo-
dopa compared with those treated with pramipexole.
In fact, HRQOL gains, measured using EQ-5D, in
years 3 and 4 for those treated with pramipexole were
signiﬁcantly greater (P < 0.05) than for those treated
with levodopa. What are the possible explanations for
these observed differences in HRQOL gains over time?
One possible factor that may contribute to the
observed difference in HRQOL by treatment arm is
differential, by treatment, dropout: more subjects in
pramipexole group (n = 67) prematurely withdrew
compared with subjects in levodopa group (n = 49). A
widening difference in HRQOL proﬁles could be
explained if relatively more dropouts in the pramipex-
ole group were “treatment-related” whereas in the lev-
odopa group relatively more dropouts were primarily
“disease progression-related.” As a consequence of
this, after dropout, the pramipexole subjects would
experience relative improvements compared with lev-
odopa subjects. There is some evidence for that.
Except for somnolence and edema (16 people in
pramipexole arm vs. one in levodopa arm), other rea-
sons for leaving the trial were distributed similarly
between the treatment arms [2]. Notably, even under
the assumptions that are most favorable to levodopa
(that quality of life worsens after dropout in the prami-
pexole arm and improves in the levodopa arm), we
ﬁnd greater HRQOL gains in the pramipexole group
(although not statistically signiﬁcant). Under the oppo-
site set of assumptions (those that relatively favored
pramipexole), the differences in HRQOL between the
treatment arms were even greater and statistically
signiﬁcant. This conﬁrms that the cause of dropouts
matters.
Differences in the levels of HRQOL at randomiza-
tion could be another possible explanation of the rel-
atively larger gains among those in the pramipexole
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group. Because subjects in the pramipexole group had
lower HRQOL at baseline, their relative improvement
compared with those in the levodopa group could be
explained by regression to the mean. There were, how-
ever, only four subjects, all in the pramipexole group,
that had particularly low HRQOL at baseline. Analy-
ses that excluded these four subjects found both that,
among the remaining subjects, HRQOL were balanced
at baseline, and that the main substantive results were
not changed, suggesting that regression to the mean is
unlikely to explain our ﬁndings.
Comparison across various imputation techniques
revealed that regardless of the imputation approach,
HRQOL was higher in pramipexole arm during the
4 years of therapy, but the QALY gain was not signif-
icant. The FE imputation approach had a more pro-
nounced effect on the pramipexole arm compared with
other approaches. One explanation for that is that the
individuals who dropped out of the pramipexole arm
had overall good health that declined right before the
dropout (the last visit). Hence, incorporating the indi-
vidual “ﬁxed effect” component along with baseline
patient information brought the imputed values up
compared with other methods. One can see the trend
that as the imputation technique becomes more sophis-
ticated (from LOCF to IOM to LOS to FE), the treat-
ment arms grow further apart. This trend indicates
that in addition to MAR; the basic assumption for all
utilized imputation techniques, there is a systematic
component of HRQOL that is conditional on observed
subject characteristics. To utilize more fully the avail-
able information, the FE approach seems appropriate.
These results are in line with the earlier study [2]
that  deﬁned  and  measured  treatment  effectiveness
as the difference between the baseline and ﬁnal (at
208 weeks) EQ-5D scores, delta EQ-5D, and con-
cluded that there was no difference, by treatment.
Our approach estimates treatment effectiveness using
QALY, the product of EQ-5D and time. This approach
takes advantage of the entire EQ-5D proﬁle, rather
than using only two data points (the ﬁrst and the last).
Nevertheless, the results of both approaches, as well as
of all other imputation methods we tested, concluded
that  there  was  no  statistically  signiﬁcant  difference
in HRQOL over 4 years. Our study explores the
HRQOL proﬁles to examine the dynamic differences
in HRQOL over time because one of the a priori
assumptions about pramipexole is that it may have a
long-term effect by delaying use of levodopa and
related dyskinesias. Using several approaches, includ-
ing the FE imputation, we found statistically signiﬁ-
cant differences in the annual QALY gains in the later
years, by treatment.
Further research is also needed to better understand
the meaning of incremental changes in preference-
based health measures, and to help understand the
strengths and weakness of various HRQOL measures
[38]. What does a gain in 0.149 QALY mean over a 4-
year period? Using willingness-to-pay approach as one
benchmarking method, 0.149 QALY would be valued
at $7450 using $50,000/QALY or approximately
$30,000 assuming a more realistic societal value of
$200,000 per QALY gained based on historical spend-
ing patterns [39,40]. Other anchor-based methods can
be used to help establish the meaning of gains and
losses of HRQOL over time [38]. Our results suggest
that preference-based measures can provide valuable
information beyond traditional disease-speciﬁc impair-
ment and disability scales.
Because preferences incorporate patient’s perspec-
tive on all aspects of therapy, physicians should take
patient’s preference into account especially when there
is no clear medical evidence or recommendation about
the preferred choice. Although it appears that these
two treatment options are differentially affecting
HRQOL over time, more work is needed to determine
whether the magnitude and strength of these changes
represent clinically meaningful differences to help
guide treatment decisions.
In summary, subjects randomized to initial prami-
pexole compared with initial levodopa in early PD
showed distinct HRQOL proﬁles over time. The
HRQOL gains associated with pramipexole become
more apparent in years 3 and 4 after initiation of the
therapy that certainly raises the possibility that a
longer-term study would show even larger gains. Our
results  also  raise  the  possibility  that  pramipexole
may be improving HRQOL through nonmotor mech-
anisms. The common pramipexole-associated side
effects of somnolence and edema did not have sig-
niﬁcant negative effects on HRQOL. Continued
follow-up of this cohort may help determine whether
the relative improvements due to pramipexole are last-
ing and help unravel the pathways through which
these two treatment options are differentially affecting
HRQOL over time.
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in Chicago, Illinois, October 2003. The authors would like to
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